Our organoid and immune cell co-culture platform can be used to evaluate new immunomodulatory compounds such as bi-specifics, checkpoint inhibitors, or CAR-T cells. Our standardized assay format allows to measure reactivity of high-dose-IL-2 expanded, unbiased/polyclonal Tumor-Infiltrating Lymphocytes (TIL) against paired cancer patient-derived HUB Organoids™. TILs reactivity is measured by quantifying the level of induced tumor organoid cell death. If paired TIL are not available, non-paired T cell clones and HLA-matched peptide pulsed organoids can be exploited.
On request, we can set up specific assays that are not listed and which we have not yet developed.